Welcome to our dedicated page for Evofem Bioscienc news (Ticker: EVFM), a resource for investors and traders seeking the latest updates and insights on Evofem Bioscienc stock.
Evofem Biosciences commercializes FDA-approved sexual and reproductive health products for women’s health. Its product portfolio includes PHEXX® (lactic acid, citric acid and potassium bitartrate), a hormone-free contraceptive vaginal gel, and SOLOSEC® (secnidazole) 2g oral granules, an oral antibiotic for bacterial vaginosis and trichomoniasis.
Company news commonly covers product sales, operating results, commercialization partnerships, distribution agreements and international regulatory activity for PHEXX and SOLOSEC. Updates also include manufacturing and supply arrangements, stockholder votes, capital-market actions and education or advocacy initiatives tied to women’s health communication.
Evofem (OTC: EVFM) reported Q1 2026 net sales of $0.9 million, up from $0.8 million a year earlier, driven by higher WAC, improved gross-to-net for PHEXX and SOLOSEC, and higher SOLOSEC ex-factory sales.
Operating expenses were $5.5 million versus $6.1 million (excluding a prior one-time $5.6 million R&D reduction). Net loss was $5.5 million, or $(0.04) per share, compared with Q1 2025 net income of $1.0 million. Evofem expanded into Sub-Saharan Africa via a SOLOSEC distribution deal, continued UAE regulatory review for PHEXX and SOLOSEC, and advanced enrollment in an NIH-funded Phase 4 SOLOSEC trial.
Evofem (OTCID: EVFM) entered an exclusive Distribution Agreement with Clovis Davis Pharmaceuticals to commercialize SOLOSEC® (secnidazole) 2g oral granules across sub-Saharan Africa, announced April 27, 2026. SOLOSEC is FDA‑approved as a single‑dose oral treatment for bacterial vaginosis (BV) and trichomoniasis in people 12 years and older. Clovis Davis will lead distribution, promotion, marketing, and sales and will deploy the OSOM BVBlue point‑of‑care BV diagnostic in Ethiopia and Uganda. Local regulatory filings in the Territory will be based on Evofem’s FDA registration dossier.
Evofem Biosciences (OTCID: EVFM) reported record $20.2 million net sales for FY2025, marking its fifth consecutive year of net sales growth. Total operating expenses fell 38% to $16.8 million, producing operating income of $3.4 million and net income attributable to common stockholders of $0.3 million (basic and diluted $0.00).
Q4 net sales were $9.6 million (up 35% year-over-year). Cost reductions included a $5.6M trade payable settlement gain and a $1.9M non-cash accounting gain; company targets 55–60% manufacturing cost reductions for PHEXX and SOLOSEC.
Evofem (OTCID: EVFM) announced that CEO Saundra Pelletier’s keynote, “Rebuilding Women’s Health from the Ground Up,” from Fierce JPM Week 2026 is available on demand. Pelletier called for a “ground-up reset” of women’s health, criticized exclusionary legacy clinical practices, and outlined Evofem’s emphasis on transparency, education, and respect in product development and leadership.
Fierce Pharma offers free on-demand access; attendees can register, log in, and select the Friday, January 23 session at 9:25–9:50am to view.
Evofem Biosciences (OTCID: EVFM) announced on January 21, 2026 the launch of the Say Vagina Store, expanding its Say Vagina campaign to normalize accurate female anatomical language and advance education and autonomy in women’s health.
The store is positioned as an extension of the campaign’s advocacy and educational work addressing perceived censorship and algorithmic suppression of clinical terms, and will support awareness, dialogue, and cultural change. The campaign will be further highlighted at a featured SXSW 2026 panel on platform censorship and algorithm impacts on women’s health. The store is available at www.SayVaginaStore.com.
Evofem Biosciences (OTCID: EVFM) announced that the Emirates Drug Establishment (EDE) issued favorable pricing certificates for PHEXX on Nov 21, 2025, a preliminary administrative step toward UAE regulatory approval.
Pharma 1, Evofem's licensee, holds exclusive commercialization rights for PHEXX and SOLOSEC in six GCC states with potential expansion into 15 MENA countries, and is expected to launch PHEXX in the UAE in 2026, subject to timely EDE marketing approval and other regulatory and commercial conditions. Pharma 1 will manage distribution, sales, marketing, and pharmacovigilance in the licensed territory.
Evofem (OTCID: EVFM) reported Q3 2025 results: net sales $5.0M (up 10% vs. prior-year quarter) and operating income $1.0M versus a $2.4M operating loss a year earlier. Total operating expenses fell to $4.0M, a 42% decline driven by a $1.0M decrease in G&A and a $1.9M one-time accounting gain tied to an expired Rush patent contingent royalty.
The company reported a net loss attributable to common stockholders of $1.7M (loss per share $0.01) vs. $2.4M ($0.02) in Q3 2024. Liquidity included $0.8M restricted cash at September 30, 2025. Corporate and commercial updates: submitted SOLOSEC for UAE approval, ongoing NIH-funded Phase 4 trial for SOLOSEC vs metronidazole, terminated the proposed merger with Aditxt, and advanced manufacturing cost reductions of ~50% for PHEXX and SOLOSEC.
Evofem Biosciences (OTCID: EVFM) announced on October 20, 2025 that its stockholders did not approve the Amended and Restated Merger Agreement with Aditxt (NASDAQ: ADTX), and Evofem has exercised its rights to terminate the Merger Agreement.
The company said it will pivot to regain a national listing for its stock and secure growth capital to catalyze net sales while targeting sustainable positive EBITDA in 2027. Evofem noted a continuing collaboration with Aditxt to commercialize Mitomic diagnostic tests under their September 2024 agreement.
Evofem commercializes two FDA-approved sexual health products, PHEXXI vaginal gel and SOLOSEC oral granules, and reported 2024 was its fourth consecutive year of net sales growth.
Evofem Biosciences (OTCID: EVFM) announced that its licensee Pharma 1 has submitted SOLOSEC® for marketing approval in the United Arab Emirates (UAE). SOLOSEC® is a single-dose oral treatment FDA-approved for bacterial vaginosis (BV) and trichomoniasis.
Pharma 1, which holds exclusive commercialization rights for SOLOSEC® in the Middle East, targets a 1H 2026 launch in the UAE. The market opportunity is significant, with 25-41% BV prevalence in the MENA region, representing 1.0-1.7 million women in the UAE alone. Additionally, about 4.7% of women in the general MENA population are affected by trichomoniasis.
This marks SOLOSEC's first ex-U.S. regulatory filing, representing a strategic move to expand and diversify Evofem's revenue stream.
Evofem Biosciences (OTCID: EVFM) commemorates World Contraception Day by highlighting its commitment to women's reproductive health innovation. The company's flagship products include PHEXXI®, the first hormone-free, on-demand contraceptive vaginal gel, and SOLOSEC®, a single-dose treatment for bacterial vaginosis and trichomoniasis.
CEO Saundra Pelletier emphasizes the importance of providing women with flexible contraceptive options, particularly for those who want alternatives to hormonal birth control. The company's "Say Vagina" awareness campaign has reached millions, focusing on destigmatizing women's health conversations and improving health education.